

13 August 2025

Sydney, Australia

Nyrada Appoints Consultant Cardiologist for Phase IIa Xolatrip™ Trial

Highlights:

- [Professor William Chan](#) appointed consultant cardiologist for Nyrada's upcoming Phase IIa clinical trial.
- Phase IIa will evaluate the safety and investigate the efficacy of Xolatrip™ in patients with myocardial infarction undergoing Percutaneous Coronary Intervention (PCI).

Nyrada Inc (ASX:NYR), a clinical-stage biotechnology company focused on developing TRPC Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions has appointed Professor William Chan MBBS (Hons), PhD, FRACP, FCSANZ as consultant cardiologist for its upcoming Phase IIa clinical trial. Professor Chan will provide medical oversight for the study.

Professor Chan brings exceptional expertise in interventional cardiology and clinician-led research. He serves as Professor of Medicine at the University of Melbourne and Adjunct Lecturer at Monash University and holds public clinical appointments at Western Health and The Alfred, with close affiliation to the Baker Heart & Diabetes Institute.

Nyrada's Phase IIa clinical trial of Xolatrip aims to evaluate its safety and investigate effectiveness in ST-Elevation Myocardial Infarction (STEMI) patients undergoing Percutaneous Coronary Intervention (PCI). Acute STEMI is a leading cause of death and a major contributor to the growing health economic burden. A STEMI occurs when the coronary artery is blocked, restricting blood and oxygen flow to an area in the heart, causing ischemia and this region to become infarcted.

Nyrada CEO James Bonnar commented: "We are pleased to welcome Professor Chan to the team. His deep expertise in cardiovascular disease, both as a clinician and researcher, will be invaluable to the successful execution of our trial."

-ENDS-



About Nyrada Inc.

Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp™, has shown efficacy in both cardioprotection and neuroprotection, and has just completed a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chair on behalf of the Board.

Investors and Media:

Dimitri Burshtein

T: 02 9498 3390

E: info@nyrada.com

Company Secretary:

David Franks

T: 02 8072 1400

E: David.Franks@atomicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

For personal use only